2017

Policies for pre-eclampsia and eclampsia prevention and management in Bangladesh

Kanij Sultana  
*Population Council*

Amy Dempsey  
*Population Council*

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-rh


How does access to this work benefit you? Let us know!

**Recommended Citation**


This Brief is brought to you for free and open access by the Population Council.
POLICIES FOR PRE-ECLAMPSIA AND ECLAMPSIA PREVENTION AND MANAGEMENT

Each day, more than 830 women and 7,200 babies die from pregnancy- or childbirth-related causes. These complications also lead to 7,000 stillbirths daily. Ninety-nine percent of these deaths occur in developing countries. Despite global efforts to reduce preventable maternal and newborn mortality, Bangladesh still experiences between 5,000 and 6,000 maternal deaths each year. Of those deaths, 20 percent are from pre-eclampsia and eclampsia (PE/E), the second most common direct cause of maternal mortality in the country. These deaths are preventable.

In Bangladesh, best practices to prevent PE/E using aspirin and calcium and manage through task sharing and using magnesium sulphate (MgSO₄) and antihypertensive drugs have not been optimally examined.

RESEARCH

To appreciate the enormity of the problem, the Population Council conducted a landscape analysis in 12 upazilas in four districts. The study was cross sectional, and data collection activities included in-depth interviews (IDIs) with policy makers, development partners, program managers, and Ob/Gyn professionals and primary facility providers. The study’s objective was to identify existing national policies and guidelines for PE/E management and prevention, as well as to document gaps in antenatal care (ANC) specifically related to PE/E.

Recommendations

- Communicate national PE/E policy and guidelines to all stakeholders, program managers, and service providers.
- Distribute national policies throughout the health system, including primary facilities.
- National policies include prevention and management of PE/E protocols at secondary and tertiary facilities.
- Train providers at primary and secondary facilities on prevention and management of PE/E.
- Collaborate with pharmaceutical companies to manufacture and package single IM loading dose of MgSO₄.
- Introduce task sharing policy for the administration of aspirin and antihypertensive drugs by primary facility providers.
Central Medical Store of Drugs (CMSD) to District Reservation Stores (DRS). If these medicines are supplied to DRS, they are either stored there or sent to the district hospitals (DH) or upazila health complexes (UHC), depending upon the need.

The DGHS allocates 20 percent of its budget to the CMSD to locally procure medicines, including antihypertensive drugs, usually purchased quarterly through CMSD or by local purchase through a competitive bidding process. In exploring the reasons for irregular supply of these drugs, where the incidence of PE/E is lower, facilities appear to not use the drugs frequently and many drugs in expire on the shelves.

Prevention measures

Aspirin is not seen as a preventive drug for PE/E and there is no policy. Calicum is regularly supplied to pregnant women during ANC, although many providers are unaware of its use in preventing pre-eclampsia.

Improving the referral system

Interviewees were evenly divided about functionality of the current referral system. Half of the respondents believe it functions well, while others disagree. All believe it needs to be strengthened, however.

“We say that we made progress toward the MDG goals, but still most of the deliveries are taking place at home. If there is any problem, they first come to the grass roots health workers. If we can make the service providers more aware and train them at the community level, then they can identify PE/E, administer the loading dose of MgSO₄ and refer. Then it will definitely have a good effect and will reduce maternal mortality.”

UNFPA Participant

Essential drugs for PE/E

Magnesium sulphate, calcium gluconate and antihypertensive drugs are essential for providing comprehensive treatment of PE/E. The Directorate General of Family Planning (DGFP) does not supply these drugs to its facilities, rather, they expect pregnant women presenting with PE/E to be referred to a higher level facility with the appropriate medicines. In the Directorate General of Health Services (DGHS), MgSO₄ and calcium gluconate (the antidote to MgSO₄ toxicity) are supplied irregularly by the

FOR MORE INFORMATION

Kanjij Sultana at Kanij.Sultana@popcouncil.org, info@endingeclampsia.org
For more information, visit www.endingeclampsia.org.